Evidence map›Paper›PMID 31115626›Full record

Trial reportEuropean radiology2019

Composite criteria using clinical and FDG PET/CT factors for predicting recurrence of hepatocellular carcinoma after living donor liver transplantation.

Yeon-Koo Kang, Joon Young Choi, Jin Chul Paeng, Yong-Il Kim, Hyun Woo Kwon, Gi Jeong Cheon, Kyung-Suk Suh, Choon Hyuck David Kwon, Dong Soo Lee, Keon Wook Kang

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European radiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Spectrum of therapeutic options in hepatocellular carcinoma.Journal of exercise rehabilitation · 2025
    Review
  3. Review
  4. The application ofQuantitative imaging in medicine and surgery · 2023
    Review
  5. Impact of metabolic indices ofJournal of cancer research and clinical oncology · 2023
    Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yeon-Koo KangDepartment of Nuclear Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, South Korea.
Joon Young ChoiDepartment of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Jin Chul PaengDepartment of Nuclear Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, South Korea. paengjc@snu.ac.kr.ORCID http://orcid.org/0000-0002-7464-9342
Yong-Il KimDepartment of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Hyun Woo KwonDepartment of Nuclear Medicine, Korea University Anam Hospital, Seoul, South Korea.
Gi Jeong CheonDepartment of Nuclear Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, South Korea.
Kyung-Suk SuhDepartment of Surgery, Seoul National University College of Medicine, Seoul, South Korea.
Choon Hyuck David KwonDepartment of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Dong Soo LeeDepartment of Nuclear Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, South Korea.
Keon Wook KangDepartment of Nuclear Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, South Korea.

Funding

Ministry of Health and Welfare HI14C1277
6 · The paper itself

Abstract

objectivesFluorodeoxyglucose (FDG) PET/CT is effective for predicting recurrence of hepatocellular carcinoma after liver transplantation. This study aimed to design composite criteria for predicting post-transplantation recurrence using clinical and FDG PET/CT factors.

methodsWe retrospectively enrolled 239 patients who underwent living donor transplantation in two independent centers between 2005 and 2013. On PET, maximum tumor-to-background ratio (TBR

resultsTumor size, number, alpha-fetoprotein, and TBR

conclusionsThe composite criteria adding FDG PET findings to clinical factors are effective in selecting appropriate liver cancer patients who are candidates for liver transplantation. KEY POINTS: • In patients with HCC, tumor uptake on FDG PET/CT, tumor size, number, and serum AFP level are recognized individual predictors for tumor recurrence after LT. • A composite criterion set, combining tumor size, number, serum AFP level, and maximum tumor-to-background ratio (TBR

Indexed as

Living DonorsAdultAgedalpha-FetoproteinsBiomarkers, TumorCarcinoma, HepatocellularFemaleFluorodeoxyglucose F18HumansLiver NeoplasmsLiver TransplantationMaleMiddle AgedNeoplasm Recurrence, LocalPatient SelectionPositron Emission Tomography Computed TomographyAFP protein, humanalpha-FetoproteinsBiomarkers, TumorFluorodeoxyglucose F18RadiopharmaceuticalsHepatocellular carcinomaPositron emission tomographyRecurrenceTransplantation

Identifiers

PMID31115626

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.